A drug under trial reduces risk of heart attack, stroke
An experimental drug by Eli Lilly, called lepodisiran, has shown promising results in lowering Lp(a) levels, a particle linked to heart attack and stroke risk, by 94% with just one injection. While more studies are needed to confirm its effectiveness, this breakthrough could be significant for those with elevated Lp(a) levels, as existing treatments are limited.
An experimental drug by Eli Lilly, called lepodisiran, has shown promising results in lowering Lp(a) levels, a particle linked to heart attack and stroke risk, by 94% with just one injection. While more studies are needed to confirm its effectiveness, this breakthrough could be significant for those with elevated Lp(a) levels, as existing treatments are limited.
